Core Insights - The company reported a revenue of 50.961 million, representing a year-on-year increase of 703.8% [1] - Gross profit reached 29.369 million, showing a significant year-on-year growth of approximately 1716% [1] - The net loss narrowed to 75.483 million, a reduction of 78.53% compared to the previous year [1] - The loss per share was recorded at 0.14 yuan [1] Financial Performance - Revenue: 50.961 million, up 703.8% year-on-year [1] - Gross Profit: 29.369 million, up approximately 1716% year-on-year [1] - Net Loss: 75.483 million, down 78.53% year-on-year [1] - Loss per Share: 0.14 yuan [1] Factors Influencing Performance - The reduction in loss was primarily attributed to decreased R&D expenses, lower administrative costs, an increase in net foreign exchange gains, and higher gross profit [1]
科济药业-B公布中期业绩 净亏损7548.3万元 同比收窄78.53%